SynthesisOntario health technology assessment series2023

Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.

Ontario Health (Quality)PubMed ↗Full text ↗

No numbers read from the abstract.